Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation ⓘValue Creation Index Colour Code Guide ⓘ
|ROCE % ⓘ||10.6%||-65.4%||-9.6%||-13%||3.6%||10.8%||11.1%||19.7%||22%||22.7%||-|
|Value Creation Index ⓘ||-0.3||-5.7||-1.7||-1.9||-0.8||-0.2||-0.2||0.4||0.6||0.7||-|
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ
|YoY Gr. Rt. %||-||-26.5%||21.4%||9.1%||9%||-3.6%||5%||27.6%||14.2%||-2.2%||-|
|Adj EPS ⓘ||7.8||-37.8||-5.2||-8.4||2.2||8.2||10.5||21.6||28.9||36.9||28.2|
|YoY Gr. Rt. %||-||-585.9%||NA||NA||NA||274.3%||28.1%||106.5%||34.1%||27.4%||-|
|BVPS (₹) ⓘ||75.7||39.9||68.6||60.3||62.4||88.5||97.9||119.5||145.1||181.8||189.2|
|Adj Net Profit ⓘ||19.5||-94.5||-13||-21||5.5||20.4||26.1||54||72.3||92.2||71|
|Cash Flow from Ops. ⓘ||38.7||-6||-0.8||-45.7||57||38.1||8.8||55||87.4||105||-|
|Debt/CF from Ops. ⓘ||0||0||0||0||0||0||0||0||0||0||-|
CAGR ⓘCAGR Colour Code Guide ⓘ
|9 Years||5 Years||3 Years||1 Years|
|Adj EPS ⓘ||18.9%||76%||52.2%||27.4%|
Key Financial Parameters ⓘPerformance Ratio Colour Code Guide ⓘ
|Return on Equity % ⓘ||10.6||-65.4||-9.6||-13||3.6||10.8||11.1||19.7||21.7||22.5||15.2|
|Op. Profit Mgn % ⓘ||5.8||-17.5||-2.7||-2.2||3||6.9||8.2||9.8||14.6||16.7||13.4|
|Net Profit Mgn % ⓘ||3.7||-24.2||-2.8||-4.1||1||3.8||4.6||7.4||8.7||11.3||9|
|Debt to Equity ⓘ||0||0||0||0||0||0||0||0||0||0||0|
|Working Cap Days ⓘ||117||171||155||173||167||185||216||177||168||194||298|
|Cash Conv. Cycle ⓘ||55||51||17||11||17||11||12||0||-2||0||149|
Sales growth is growing at healthy rate in last 3 years 12.53%
Net Profit is growing at healthy rate in last 3 years 52.22%
Return on Equity has declined versus last 3 years average to 15.20%
Sales growth is not so good in last 4 quarters at -4.42%
|TTM EPS (₹)||28.2||-|
|TTM Sales (₹ Cr.)||784||-|
|BVPS (₹.) ⓘ||189.2||-|
|Reserves (₹ Cr.) ⓘ||468||-|
|From the Market|
|52 Week Low / High (₹)||2930.00 / 4580.00|
|All Time Low / High (₹)||9.00 / 4970.00|
|Market Cap (₹ Cr.)||7,663|
|Equity (₹ Cr.)||5|
|Face Value (₹)||2|
|Industry PE ⓘ||41.2|
Astrazeneca Pharma India (AZPIL) incorporated on 11 July, 1979 is engaged in the business of manufacturing and marketing pharmaceutical products in healthcare segments namely gastrointestinal, cardiovascular, cancer, respiratory, neurosciences and infection. The company has an innovative portfolio in crucial areas of healthcare including cardiovascular, renal & metabolic diseases, oncology and respiratory. AstraZeneca Pharma India is a subsidiary of AstraZeneca Pharmaceuticals AB, Sweden, which is an indirect subsidiary of AstraZeneca PLC.
The company’s Global Technology Centre (GTC) in Chennai, is its primary insourced IT facility delivering significant value to the business through an end-to-end, integrated IT service delivery mode. The centre was set up in September 2014 in Chennai, Tamil Nadu, India with the mandate to deliver best in class IT service for the global business.
The company launched its R&D Bangalore in 2017 to support AstraZeneca’s global established medicines portfolio. The R&D Bangalore team provides support across a range of therapy areas, including oncology, respiratory and cardiovascular and metabolic diseases, with a focus on AstraZeneca’s mature brands which are used by patients around the world.
The Global Business Services (GBS), which now houses Global Commercial Operations (GCO), was set up in Chennai in 2017 and has driven efficiency across content management, multichannel marketing and analytics and reporting. GCO Global supports E2E commercial content management to markets - from creation, production, review, process, publishing and reporting. GCO helps multiple markets to avoid duplication of content leading to faster launches and cost savings.
Business area of the company
The Company is engaged in the business of manufacture, distribution and marketing of life-changing medicines in crucial areas of healthcare including oncology, cardiovascular, diabetes, renal, metabolic and respiratory.
Core Therapy Areas
Milestones and achievements